Special Issue

Mass Spectrometry-Based Lipidomics in Drugs Discovery

Message from the Guest Editors

Several human diseases, such as obesity, cardiovascular disease, cancer, and neurodegeneration, involve changes in lipids and lipid metabolic pathways. Alterations in the expression of different lipid molecules have been used to specify the functionality of various metabolic pathways in disease. In addition, the discoordination of lipids affects the upstream proteomic regulation and interaction. This information can be employed to identify druggable target enzymes to control the pathway of interest. Mass spectrometry (MS)-based lipid profiling and analysis, including liquid chromatography-high resolution mass spectrometry (LC-MS), MS imaging, and lipidomic flux analysis, hold tremendous potential in the diagnostic approach along the drug development process. In this Special Issue, we seek to bring together research from experts in the field, focusing on novel mass spectrometry-based lipidomics techniques and strategies, their applications in targeted-lipid drug discovery and development, and future perspectives that will enhance our biological understanding of molecular lipid metabolism for precise therapeutic opportunities.

Guest Editors

Dr. Hua Tian

Department of Environmental and Occupational Health, School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA

Dr. Fereshteh Zandkarimi

Department of Chemistry, Columbia University, New York, NY, USA

Deadline for manuscript submissions

closed (31 December 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/171524

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

